Supplementary_data_(R1).pdf (251.49 kB)
Download file

Hepatic Insulin Resistance Is Not Pathway Selective in Humans With Nonalcoholic Fatty Liver Disease

Download (251.49 kB)
figure
posted on 08.12.2020, 22:23 by Kasper W. ter Horst, Daniel F. Vatner, Dongyan Zhang, Gary W. Cline, Mariette T. Ackermans, Aart J. Nederveen, Joanne Verheij, Ahmet Demirkiran, Bart A. van Wagensveld, Geesje M. Dallinga-Thie, Max Nieuwdorp, Johannes A. Romijn, Gerald I. Shulman, Mireille J. Serlie
Objective: Both glucose and triglyceride production are increased in Type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). For decades, the leading hypothesis to explain these paradoxical observations has been selective hepatic insulin resistance, wherein insulin drives de novo lipogenesis (DNL), while failing to suppress glucose production. Here, we aimed to test this hypothesis in humans.

Research Design and Methods: We recruited obese subjects who met criteria for bariatric surgery with (n=16) or without (n=15) NAFLD and assessed: i) insulin-mediated regulation of hepatic and peripheral glucose metabolism using hyperinsulinemic-euglycemic clamps with [6,6-2H2]glucose, ii) fasting and carbohydrate-driven hepatic DNL using deuterated water (2H2O), and iii) hepatocellular insulin signaling in liver biopsies collected during bariatric surgery.

Results: As compared with subjects without NAFLD, subjects with NAFLD demonstrated impaired insulin-mediated suppression of glucose production and attenuated -not increased- glucose-stimulated/high-insulin lipogenesis. Fructose-stimulated/low-insulin lipogenesis was intact. Hepatocellular insulin signaling, assessed for the first time in humans, exhibited a proximal block in insulin-resistant subjects: signaling was attenuated from the level of the insulin receptor through both glucose and lipogenesis pathways. The carbohydrate-regulated lipogenic transcription factor ChREBP was increased in subjects with NAFLD.

Conclusions: Acute increases in lipogenesis in humans with NAFLD are not explained by altered molecular regulation of lipogenesis through a paradoxical increase in lipogenic insulin action; rather, increases in lipogenic substrate availability may be the key.

Funding

KWH and MJS are supported by EU (FP7-EU 305707); DFV by NIH (R01 DK124272, K23 DK10287); MN by ZonMw (VIDI 016.146.327) and Dutch Heart Foundation (CVON IN-CONTROL); GIS by NIH (R01 DK113984, R01 DK119968, and P30 DK45735). MJS receives unrestricted research funding from Mediq TEFA (Utrecht, Netherlands).

History